Filter by category:
Anaplastic Thyroid Cancer
Not Currently Available
Electron Kebebew, MD(Speaker)
Stanford University, Stanford, California, USA
Electron Kebebew, MD, is an internationally recognized expert in Endocrine Oncology and Surgery. He has performed more than three thousand operations on the adrenal, parathyroid and thyroid glands, and for neuroendocrine tumors of the gastrointestinal tract and pancreas. Dr. Kebebew has published over 400 articles, chapters and textbooks, and serves on the editorial board and as a reviewer for 54 biomedical journals. He has received awards from the American Cancer Society, American Association for Cancer Research, American Thyroid Association, American Association of Endocrine Surgeons, and International Association of Endocrine Surgeons.

Disclosures:

No relevant financial relationships.
Tim Korevaar, MD, PhD(Moderator)
Erasmus University Medical Center, Rotterdam, Netherlands
Tim Korevaar, MD, PhD, obtained his medical degree at the Erasmus University Medical Center, Rotterdam, the Netherlands in 2013 and an MSc in clinical epidemiology at the Netherlands Institute of Health Sciences in 2015. He obtained his PhD for studies on determinants, interpretation and consequences of thyroid hormone availability during pregnancy and early life at the Erasmus University Medical Center (Cum Laude) in 2017 for which he was awarded with the Dutch Endocrine Society Thesis Award. After his PhD, he did a postdoctoral research internship at the Harvard School of Public Health (Boston, USA) studying thyroid function and fertility, and thyroid disruptors. Tim has been the recipient of the British Thyroid Award, the Society for Endocrinology Early Career Prize Lectureship award, the European Society of Endocrinology Young Investigator award and has published over 55 peer-review scientific publications and various book chapters.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify the newest staging system for anaplastic thyroid cancer
  • Summarize the newest anaplastic cancer practice guidelines and how to implement these changes in order to improve patient care
  • Recognize novel treatment opportunities for anaplastic thyroid cancers.
Ancillary Symposium: Hypophosphatemia: Unlocking The Key To Improved Diagnosis And Management
Not Currently Available
Introduction, Pre-Test Questions
Michael A. Levine, MD
Children Hospital of Philadelphia, Philadelphia, Pensylvania, USA
Dr. Levine is Chief Emeritus of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia. Dr. Levine holds the Lester Baker Endowed Chair and is Professor Emeritus of Pediatrics and Medicine at the University of Pennsylvania Perelman School of Medicine.

Dr. Levine’s research interests focus on the genetic basis of endocrine diseases that affect bone and mineral metabolism, particularly rickets, primary hyperparathyroidism, and hypoparathyroidism. Dr. Levine has published over 400 manuscripts, chapters, and reviews. He is a former Editor of the Journal of Clinical Endocrinology and Metabolism, and has served as a member of the Board of Directors of the U.S. Pediatric Endocrine Society.

He has received numerous awards in recognition of his accomplishments as a physician scientist, including the Distinguished Endocrinology Award from the American College of Endocrinology, the Frederic C. Bartter Award from the American Society of Bone and Mineral Research, and the International Award from the European Society for Pediatric Endocrinology.

Disclosures:

Research Investigator, Ultragenyx Pharmaceuticals
X-linked Hypophosphatemia Update: History and Future Goals of Treatment
Leanne M. Ward, MD
Unversity of Ottawa, Ottawa, Ontario, Canada
Leanne Ward is a Professor of Pediatrics at the University of Ottawa where she has held a Research Chair in Pediatric Bone Health since 2010. She is the Scientific Director of the Ottawa Pediatric Bone Health Research Group, the Medical Director of the Genetic and Metabolic Bone Disease Clinic at the Children’s Hospital of Eastern Ontario (CHEO), and a pediatric endocrinologist in the Division of Endocrinology and Metabolism at CHEO. Dr. Ward is also the Founder and Chair of the Canadian Consortium for Children’s Bone Health, a national working group dedicated to the care and study of children with bone disorders.
Leanne is actively involved in a number of clinical trials for children with bone fragility disorders such as osteogenesis imperfecta, rickets (including X-linked hypophosphatemia), and chronic illness osteoporosis. She has served as an endocrinology and bone health advisor to various international organizations including the Centres for Disease Control Clinical Care Considerations for Duchenne Muscular Dystrophy (DMD), the International Late Effects of Childhood Cancer Guideline Harmonization Group, the International Society for Clinical Densitometry, Soft Bones Canada, Parent Project Muscular Dystrophy, and the International Conference on Children’s Bone Health.
Dr. Ward has been the principal investigator of the “STOPP” research program (STeroid-associated Osteoporosis in the Pediatric Population) since 2003, a pan-Canadian project funded by the Canadian Institutes of Health Research to evaluate the effect of glucocorticoids on bone health in children with chronic illnesses. This multi-centre longitudinal research program has unveiled the natural history of osteoporotic fractures in children with steroid-treated disorders, including the clinical hallmark of this disorder in children, vertebral fractures. The results of the STOPP Consortium’s work under Dr. Ward’s leadership have played a major role in informing the approach to the diagnosis of steroid-induced osteoporosis in children, to the monitoring of those at risk, and in identifying children in need of osteoporosis prevention and intervention.
Dr. Ward has received a number of awards for her work in pediatric bone health, including a Canadian Child Health Clinician Scientist Career Development Award, a Canadian Institutes for Health Research New Investigator Award, a Canadian Child Health Clinician Scientist Career Enhancement Award, and three, five-year Research Chairs in Pediatric Bone Disorders from the University of Ottawa (2010, 2015, and 2020).
In 2019, Dr. Ward was named a Fellow of the American Society of Bone and Mineral Research, an award in recognition of significant contributions to the Society, and to bone and mineral science.
Tumor-Induced Osteomalacia Diagnosis and Tumor-Induced Osteomalacia Management and Therapeutic Goals
Michael A. Levine, MD
Children Hospital of Philadelphia, Philadelphia, Pensylvania, USA
Patient Case
Leanne M. Ward, MD
Unversity of Ottawa, Ottawa, Ontario, Canada
Audience Q&A
All
supported by:
Ultragenyx Pharmaceuticals
 

Learning Objectives:

  • Evaluate the pros and cons of different imaging techniques for identifying tumor-induced osteomalacia
  • Identify symptoms to encourage evaluation for phosphorous management
  • Discuss optimal approaches to XLH management
Ancillary Symposium: Keeping Sight of Thyroid Eye Disease
Not Currently Available
Overview of TED Pathophysiology
Terry J. Smith, MD
University of Michigan Medical School, Ann Arbor, Michigan, USA
Terry J. Smith, MD, the Frederick G.L. Huetwell Professor in Ophthalmology and Visual Sciences and Internal Medicine at the University of Michigan Medical School, studies Graves’ disease, its ocular manifestations, and related autoimmune diseases. Dr. Smith’s laboratory has described many unique molecular attributes of tissues surrounding the eye that make the orbit susceptible to inflammation and remodeling in Graves' disease. His investigation of these mechanisms has yielded several potential therapeutic targets that may interrupt the disease process. Among these, the insulin-like growth factor I receptor was implicated in the pathogenesis of thyroid-associated ophthalmopathy by his group and its inhibition has recently been shown to hold great therapeutic promise in thyroid-associated ophthalmopathy. Dr. Smith received his medical degree from the University of Missouri School of Medicine and completed his postdoctoral training at the University of California, San Francisco, Columbia University, and the University of Chicago. His laboratory has been supported continuously by the NIH and/or the VA for over 35 years.

Disclosures:

Consultant, Novartis, Merck, Lithera, Immunovant, River Vision, Horizon Therapeutics; Research Grant Support, NIH, NEI
Clinical Features: Improving Diagnosis
Don O. Kikkawa, MD
UC San Diego Health, La Jolla, California, USA
Don O. Kikkawa, MD, is Professor of Clinical Ophthalmology, Chief of the Division of Ophthalmic Plastic and Reconstructive Surgery, and Vice Chairman at the University of California at San Diego (UCSD) Department of Ophthalmology and UCSD Shiley Eye Institute in La Jolla. Dr. Kikkawa joined the UCSD Ophthalmology faculty in 1993 and is co-director of the UCSD Thyroid Eye Center and also a former program director of UCSD's ophthalmology residency. Dr. Kikkawa earned a BA (magna cum laude) in biochemistry from UCSD, La Jolla and an MD (magna cum laude) from St. Louis University School of Medicine, St. Louis, Missouri. He completed his internship at the UCSD, his residency at Jules Stein Eye Institute (UCLA) and a fellowship in Ophthalmic Plastic and Orbital Surgery at the University of Wisconsin, Madison. Dr. Kikkawa's clinical interests include aesthetic and reconstructive oculofacial surgery; orbital surgery; thyroid orbitopathy; craniofacial disorders involving the eyelids and orbits; and tumors.

Disclosures:

Consultant, Horizon Therapeutics; Book Royalties, Elsevier Publishing
Current and Emerging Therapeutic Landscape
Don O. Kikkawa, MD(Panelist)
UC San Diego Health, La Jolla, California, USA
Don O. Kikkawa, MD, is Professor of Clinical Ophthalmology, Chief of the Division of Ophthalmic Plastic and Reconstructive Surgery, and Vice Chairman at the University of California at San Diego (UCSD) Department of Ophthalmology and UCSD Shiley Eye Institute in La Jolla. Dr. Kikkawa joined the UCSD Ophthalmology faculty in 1993 and is co-director of the UCSD Thyroid Eye Center and also a former program director of UCSD's ophthalmology residency. Dr. Kikkawa earned a BA (magna cum laude) in biochemistry from UCSD, La Jolla and an MD (magna cum laude) from St. Louis University School of Medicine, St. Louis, Missouri. He completed his internship at the UCSD, his residency at Jules Stein Eye Institute (UCLA) and a fellowship in Ophthalmic Plastic and Orbital Surgery at the University of Wisconsin, Madison. Dr. Kikkawa's clinical interests include aesthetic and reconstructive oculofacial surgery; orbital surgery; thyroid orbitopathy; craniofacial disorders involving the eyelids and orbits; and tumors.
Terry J. Smith, MD(Panelist)
University of Michigan Medical School, Ann Arbor, Michigan, USA
Audience Q&A
All
supported by:
Horizon Therapeutics
 

Learning Objectives:

  • Describe the basic pathophysiology of Graves’ disease and thyroid eye disease
  • Analyze early signs and symptoms of thyroid eye disease, including criteria for stratifying mild, moderate, and severe disease, and determinants of disease activity
  • Evaluate new and emerging biological agents for treatment of thyroid eye disease
Ancillary Symposium: New Horizons for Medical Management of Acromegaly
Not Currently Available
Landscape: What’s New and What’s Changed
Shlomo Melmed, MB ChB
Cedars-Sinai Medical Center, Los Angeles, California, USA
Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).

Disclosures:

Consultant, Chiasma Inc, Ionis, Crinetics, Ipsen; Research Grant Support, Pfizer
Expanding View: Understanding Patients’ Treatment Burden and Experience
Eliza B. Geer, MD
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Eliza B. Geer, MD, joined the faculty at The Mount Sinai Medical Center in July, 2006 with an appointment in the Division of Endocrinology and a secondary appointment in the Department of Neurosurgery. After graduating from Columbia University, she attended Mount Sinai School of Medicine, graduating with Distinction in Research. She completed her Internship and Residency in Internal Medicine at Columbia Presbyterian Medical Center, where she became involved in neuroendocrine research, conducting studies on the hypothalamic-pituitary-adrenal axis and acromegaly. After completing her residency, she conducted a year of clinical research at Columbia's Obesity Research Center, funded by a NIH T32 grant, where she focused on body composition and appetite in acromegaly. She then completed a fellowship in Endocrinology, Diabetes and Bone Disease at the Mount Sinai Medical Center, graduating in 2006.

Disclosures:

Research Support, Novartis, Strongbridge, Chiasma, Ionis, Bristo-Myers Squibb; Consultant, Chiasma; Advisory Board, Strongbridge
A New Horizon: Treatment Options for Optimal Outcomes
Lawrence Katznelson, MD
Stanford School of Medicine, Stanford, California, USA
Laurence Katznelson, MD, received his medical degree from the University of California, Los Angeles and performed his internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania, Philadelphia. He then performed a fellowship in Endocrinology and Metabolism at the Massachusetts General Hospital, Boston. Dr. Katznelson is a Professor of Neurosurgery and Medicine at Stanford University School of Medicine. At Stanford University, he is the Associate Dean of Graduate Medical Education and the Chair of the GME Committee. Dr. Katznelson is currently the Medical Director of the Pituitary Center at Stanford Hospital and Clinics. In the Endocrine Society, Dr. Katznelson has served as Chair of the Special Programs and Nominations Committees. He has served as Chair of the Task Forces for writing clinical guidelines for the approach to acromegaly for both The Endocrine Society and the American Association of Clinical Endocrinologists. Dr. Katznelson has also served as Chair of the Clinical Investigator Workshop for the Endocrine Society. He is the recipient of the 2017 Laureate Award for Educator of the Year, The Endocrine Society. He is also the recipient of the H. Jack Baskin, Endocrine Teaching Award, AACE in 2015. Dr. Katznelson has a long standing clinical and research interest in the pathophysiology and treatment of pituitary disease.

Disclosures:

Research Grant Support, Chiasma Inc.; Advisory Board, Pfizer
The Journey: How to Proceed, the Decision Process
Shlomo Melmed, MB ChB
Cedars-Sinai Medical Center, Los Angeles, California, USA
Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).
Audience Q&A
All
We thank our educational partners, CMM Global, Inc.
supported by:
Chiasma, Inc.
 

Learning Objectives:

  • Examine the main aspects of acromegaly, including scientific advances and expanding knowledge of disease pathogenesis, improvements in disease management, and new medical therapies (available and in development) to improve disease control
  • Establish familiarity with current research related to patient and medical provider reporting of symptoms during treatment
  • Enhance understanding of available treatment options and the consequent outcomes (i.e., control of GH/IGF-I levels, amelioration of signs/symptoms, improved QoL, ease of administration) associated with use of these different treatment options
Atypical Diabetes: Ketosis Prone, LADA, MODY, and Pancreatogenic
Not Currently Available
Janet B. McGill, MD(Speaker)
Washington University in St. Louis, St. Louis, Missouri, USA
Janet B. McGill, MD, is a Professor Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University. She received her doctorate from Michigan State University and completed her internship and residency at William Beaumont Hospital. She has been an active clinical researcher in diabetes for over 25 years and continues to test new therapies for diabetes and novel approaches to type 1 and type 2 diabetes. Currently, Dr. McGill is the principal investigator or sub-investigator on more than 10 clinical trials investigating new treatments for diabetes and its complications and serves on planning committees and data safety monitoring boards for a number of ongoing national and international clinical trials. She is a member of the board of directors for the American Association of Clinical Endocrinologists and the AACE Diabetes Scientific Committee.

Disclosures:

Consulting/Advising: Bayer; Boehringer Ingelheim; Dexcom; Lilly; Metavant; Valeritas
Grants to Washington University: Dexcom; Medtronic; NIH/Beta Bionics; Novo Nordisk
Speaking: Janssen
Serena Cardillo, MD(Moderator)
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Serena Cardillo, MD, is a Professor of Clinical Medicine in the Division of Endocrinology, Diabetes & Metabolism in the Perelman School of Medicine at The University of Pennsylvania, where she also completed her training in internal medicine and endocrinology. Dr. Cardillo’s clinical practice is based at the Penn Rodebaugh Diabetes Center where she serves as the Director of Graduate Diabetes Education. Her clinical interests are in type 1 and type 2 diabetes, cystic fibrosis related diabetes and post-transplant diabetes. She is also an Associate Program Director and Core Faculty Member in Endocrinology for the Internal Medicine Residency Program. Her interests in graduate medical education are in ambulatory subspecialty education and the use of simulation to assess and teach communication skills. At the postgraduate level she has led several innovative national education programs in the area of diabetes management for primary care providers. Her work has been recognized in institutional teaching awards and selection as a Philadelphia Magazine Top Doctor Award in 2018.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Utilize a framework to determine in which patients to suspect atypical forms of diabetes
  • Select patients for genetic testing and targeted use of anti-hyperglycemic agents
  • Recommend glycemic management strategies tailored towards the type of atypical diabetes.
Benefits of Diabetes Agents: Beyond Blood Glucose
Available:
SEPTEMBER 10
Jennifer B. Green, MD
Duke University, Durham, North Carolina, USA
Jennifer B. Green, MD, is a Professor of Medicine in Endocrinology, Metabolism, and Nutrition at Duke University and a faculty member of the Duke Clinical Research Institute. She received her doctorate from University of Virginia and completed her residency at the University of North Carolina at Chapel Hill. Dr. Green served as chief of the Endocrinology section at the Durham VA Medical Center from 2003-2017. Her clinical and research interests focus on strategies to predict, prevent, and treat diabetes mellitus and its complications.

Disclosures:

Research Support: Boehringer Ingelheim; NIDDK; Sanofi/Lexicon
Consultant: AstraZeneca; Boehringer Ingelheim/Lilly Alliance; Novo Nordisk
 

Learning Objectives:

  • Describe the efficacy and safety of SGLT-2 inhibitor therapy in patients with renal and cardiovascular disease, and heart failure
  • Discuss the evidence to support GLP-1 receptor agonist therapy in patients with cardiovascular and renal disease
  • Apply the evidence for use of GLP-1 receptor agonist therapy in patients with obesity and non-alcoholic fatty liver disease.
CGM and Closed Loop Cases
Not Currently Available
M. Sue Kirkman, MD(Speaker)
University of North Carolina, Chapel Hill, North Carolina, USA
M. Sue Kirkman, MD, is the medical director of the UNC Diabetes Care Center’s Clinical Trials Unit, which consists of five investigators, five study coordinators, and three research assistants conducting 15-20 trials in type 1 and type 2 diabetes and in obesity. Dr. Kirkman is site principal investigator of several clinical trials including the NIDDK-funded GRADE study, for which she also serves as co-chair of the Outcomes Committee. She is also co-PI of a CDC-funded grant to better distinguish between type 1 and type 2 diabetes in adults using EHR and survey data. In addition to her clinical practice and research work, Dr. Kirkman is currently chair of the National Diabetes Education Program (NDEP), a joint initiative of NIDDK and the CDC.

Disclosures:

Research Investigator: Bayer; Novo Nordisk
Cecilia Low Wang, MD(Moderator)
University Colorado Anschutz Med Campus / School of Medicine, Aurora, Colorado, USA
Cecilia Low Wang, MD, is an Endocrinologist and Professor of Medicine at the University of Colorado Anschutz Medical Campus School of Medicine, in the Division of Endocrinology, Metabolism and Diabetes, as well as Lead Clinician-Scientist at CPC Clinical Research, an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. She is the Director of the Glucose Management Team at the University of Colorado Hospital, and Director for Housestaff and Medical Student Education for the Division of Endocrinology. Dr. Low Wang attended Pomona College and earned her medical degree from the University of Rochester School of Medicine. She completed her internship and residency at the University of Utah Health Sciences Center where she also served as Chief Medical Resident. After housestaff training, she did a clinical and research fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado School of Medicine investigating insulin action in the vascular wall with a focus on vascular smooth muscle cells, and mechanisms of atherosclerosis in diabetes.

Disclosures:

Advisory Board: BioMarin Pharmaceutical Inc.; CSL Behring GMBH
Research Investigator: Novo Nordisk; uniQure
Other: Employee at CPC Clinical Research
 

Learning Objectives:

  • Outline limitations and caveats for current diabetes technologies
  • Describe how to view data reports from CGM and hybrid closed-loop systems to work with patients to improve glycemic control
  • Use data from CGM and hybrid-closed-loop systems to recognize patterns that suggest the presence of important conditions that affect glycemic control.
Challenging Cases in Lipid Management
Not Currently Available
Savitha Subramanian, MD(Speaker)
University of Washington, Seattle, Washington, USA
Savitha Subramanian, MD, is an Associate Professor of Medicine and Metabolism, Endocrinology and Nutrition at the University of Washington Endocrine and physician at the Diabetes Care Center at University of Washington Medical Center-Roosevelt. She received her degree from Stanley Medical College in India and completed her residency at the University of Illinois College of Medicine.

Disclosures:

No relevant financial relationships.
Marc-Andre Cornier, MD(Moderator)
University of Colorado School of Medicine, Aurora, Colorado, USA
Marc-Andre Cornier, MD, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe the management of high triglycerides (below 500 mg/dL) in patients with diabetes
  • Discuss non-statin medications, and their use in patients with hypercholesterolemia taking statins
  • Define the cardiovascular risk of patients with elevated Lp(a) and the most appropriate strategies for management.
CKD and Bone Disease
Not Currently Available
Thomas J. Weber, MD(Speaker)
Duke University Medical Center, Durham, North Carolina, USA
Thomas J. Weber, MD, is an Associate Professor of Medicine at Duke University Medical Center, where he is Medical Director of the Duke Clinical Bone Laboratory, and a Clinical Investigator in the Clinical Research Training Program of the Duke University School of Medicine. He is also a permanent member of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA, and a member of the Peer Review Committee for the Endocrine Society Self-Assessment Program (ESAP). Dr. Weber has also authored the chapters on “Osteoporosis” and “Approach to the Patient with Metabolic Bone Disease” in the 25th and 26th editions of Cecil’s Textbook of Medicine. Dr. Weber attended the University of Chicago-Pritzker medical school, and thereafter completed his internship and residency training in Internal Medicine at Yale-New Haven Hospital and a research fellowship in Endocrinology at Duke University Medical Center. His research focuses on metabolic bone disease more broadly, including the hypophosphatemic, osteomalacic disorders X-linked hypophosphatemic rickets (XLH) and tumor-induced osteomalacia, as well as clinical and translational studies of osteoporosis and primary hyperparathyroidism.

Disclosures:

Editorial Consultant: Elsevier; MedIQ
Consultant/Travel Support: Pharmacosmos
Research Support/Consultant/Travel Support: Ultragenyx
The Endocrine Society - Member, Endocrine Self-Assessment Program Faculty Peer Review Committee;
Food and Drug Administration - Permanent member, Endocrine and Metabolic Drug Advisory Committee (EMDAC)
Micol Rothman, MD(Moderator)
University of Colorado Denver, Denver, Colorado, USA
Micol Rothman, MD, is an Associate Professor of Medicine-Endocrinology with secondary appointments in Radiology and Psychiatry at the University of Colorado School of Medicine. She serves as the Clinical Director of the Metabolic Bone Program and co-founder of the UC Health Integrated Transgender Program. Her research interests include the interactions of sex steroids and the bone. She received a BA with honors in classics at Brown University in Providence, R.I. in 1993. She received her MD at the Columbia University College of Physicians and Surgeons in New York in 1999. She went on to do her internship and residency in Internal Medicine at the Johns Hopkins Hospital in Baltimore, Md., and completed this training in 2002. She then spent a year working as an internist and teaching medical students at Hubert Kairuki Memorial University in Dar Es Salaam, Tanzania. Dr. Rothman completed her fellowship in Endocrinology at the University of Colorado Health Sciences Center and began working in the Endocrinology Clinic at the Anschutz Outpatient Pavilion of University Hospital in 2006. She is board certified in both Internal Medicine and Endocrinology.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Recognize the effect of renal disease on bone metabolism
  • Select patients who should undergo bone biopsy prior to initiation of pharmacologic therapy for osteoporosis
  • Prescribe appropriate osteoporosis therapy to patients with chronic renal insufficiency.
Clinical Pearls in the Management of Diabetes in Pregnancy
Not Currently Available
Linda A. Barbour, MD, MSPH(Speaker)
University of Colorado School of Medicine, Aurora, Colorado, USA
Linda A. Barbour, MD, MSPH, is a Professor in Endocrinology, Metabolism and Diabetes and Maternal-Fetal Medicine with a Masters of Science in Public Health. Her clinical and research expertise are in endocrine and metabolic diseases in pregnancy and she directs the OB Diabetes Clinic and High Risk OB Clinic at University Hospital. She was recently awarded the Norbert Freinkel award by the American Diabetes Association for her life-long teaching, clinical and research contributions to advance the care of pregnant women with diabetes and metabolic disease. She is the Past Chair for the ADA Scientific Planning Committee for Pregnancy, Past President for the North American Society of Obstetric Medicine, she served on the NIH Research Panel on Gestational Diabetes and the Endocrine Society Guidelines Panel on Thyroid Dysfunction in Pregnancy. She has been named in “Best Doctors in America” for over 20 years, authored ~100 manuscripts, chapters, or textbooks, and was recently elected to the Editorial Board of Diabetes Care

Disclosures:

No relevant financial relationships.
Serena Cardillo, MD(Moderator)
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Serena Cardillo, MD, is a Professor of Clinical Medicine in the Division of Endocrinology, Diabetes & Metabolism in the Perelman School of Medicine at The University of Pennsylvania, where she also completed her training in internal medicine and endocrinology. Dr. Cardillo’s clinical practice is based at the Penn Rodebaugh Diabetes Center where she serves as the Director of Graduate Diabetes Education. Her clinical interests are in type 1 and type 2 diabetes, cystic fibrosis related diabetes and post-transplant diabetes. She is also an Associate Program Director and Core Faculty Member in Endocrinology for the Internal Medicine Residency Program. Her interests in graduate medical education are in ambulatory subspecialty education and the use of simulation to assess and teach communication skills. At the postgraduate level she has led several innovative national education programs in the area of diabetes management for primary care providers. Her work has been recognized in institutional teaching awards and selection as a Philadelphia Magazine Top Doctor Award in 2018.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Outline clinical diagnostic considerations for diabetes in pregnancy
  • Describe key controversies in the management of T1D and T2D in pregnancy
  • Prescribe and adjust regimens for diabetes management during pregnancy while taking into consideration patient-specific factors.
Congenital Adrenal Hyperplasia: Management and Transition to Adulthood
Available:
SEPTEMBER 10
Richard Auchus, MD, PhD
University of Michigan, Ann Arbor, Michigan, USA
Richard J. Auchus, MD, PhD, is a Professor of Internal Medicine, Division of Metabolism, Endocrinology & Diabetes (MEND) and director of the MEND Fellowship Program. He received his medical degree and PhD in pharmacology from Washington University in St. Louis and completed a residency at the University of Iowa and an endocrinology fellowship at UTHSC-San Antonio/Wilford Hall Medical Center. Dr. Auchus is a steroid biologist with expertise both in basic science and clinical/translational science. His work has included translational research into molecular and genetic mechanisms of human hypertension, improved diagnostic studies and management in primary aldosteronism and Cushing syndromes, modifier genes in 21-hydroxylase deficiency, cardiovascular disease in polycystic ovary syndrome, and the endocrinology of traumatic brain injury.

Disclosures:

Consultant: Adrenas Therapeutics; Corcept Therapeutics; Janssen Pharmaceuticals; Novartis Pharmaceuticals; Quest Diagnostics; Strongbridge Biopharma
Contracted Research: Corcept Therapeutics; Neurocrine Biosciences; Novartis Pharmaceuticals; Spruce Biosciences
 

Learning Objectives:

  • Explain the main differences and goals of various types of CAH management for children and adults
  • Recognize the possible adverse consequences of overtreatment and undertreatment with currently available glucocorticoid preparations and regiments and possible future options
  • Select optimal therapy and monitoring of patients desiring fertility in setting of CAH.
Cushing Syndrome: Tips and Pitfalls in Diagnosis and Management
Available:
SEPTEMBER 10
James W. Findling, MD
Medical College of Wisconsin, Wauwatosa, Wisconsin, USA
James W. Findling, MD, is a Clinical Professor of Medicine and Director of the Community Endocrinology Center and Clinics at the Medical College of Wisconsin. He is a graduate of the University of Notre Dame and Northwestern University Medical School. He completed his internal medicine training at the Medical College of Wisconsin and his post-doctoral fellowship in Endocrinology and Metabolism at the University of California-San Francisco. He started his endocrinology practice at St. Luke’s Medical Center in Milwaukee in 1982 and he started the Endocrine-Diabetes Center at St. Luke’s in 1987. Dr. Findling has over 100 publications and book chapters and is considered an international expert on clinical disorders of pituitary and adrenal function. He discovered the importance of inferior petrosal sinus sampling for the differential diagnosis of Cushing syndrome in the early 1980s and introduced late-night salivary cortisol as a simple screening test for Cushing syndrome in the 1990s.

Disclosures:

Investigator/Consultant: Corcept Therapeutics; Novartis
 

Learning Objectives:

  • Outline the steps for evaluation and troubleshooting in patients with mild Cushing Syndrome vs Pseudo-Cushing Syndrome and discuss tips for cyclical disease evaluation
  • Describe the evaluation and management of imaging negative or equivocal imaging results in patients with ACTH dependent Cushing Syndrome
  • Identify the pros and cons of venous thromboembolism prophylaxis in patients with Cushing Syndrome.
Diagnosing Adrenal Insufficiency: Which Test in What Clinical Scenario?
Not Currently Available
James W. Findling, MD(Speaker)
Medical College of Wisconsin, Wauwatosa, Wisconsin, USA
James W. Findling, MD, is a Clinical Professor of Medicine and Director of the Community Endocrinology Center and Clinics at the Medical College of Wisconsin. He is a graduate of the University of Notre Dame and Northwestern University Medical School. He completed his internal medicine training at the Medical College of Wisconsin and his post-doctoral fellowship in Endocrinology and Metabolism at the University of California-San Francisco. He started his endocrinology practice at St. Luke’s Medical Center in Milwaukee in 1982 and he started the Endocrine-Diabetes Center at St. Luke’s in 1987. Dr. Findling has over 100 publications and book chapters and is considered an international expert on clinical disorders of pituitary and adrenal function. He discovered the importance of inferior petrosal sinus sampling for the differential diagnosis of Cushing syndrome in the early 1980s and introduced late-night salivary cortisol as a simple screening test for Cushing syndrome in the 1990s.

Disclosures:

No relevant financial relationships.
Dana Z. Erickson, MD(Moderator)
Mayo Clinic, Rochester, Minnesota, USA
Dana Z. Erickson, MD, is a Professor of Medicine at the Mayo College of Medicine in Rochester, MN. Her primary clinical interests include disorders of pituitary gland and adrenal disorders. She has been involved with clinical research in both of these areas, with particular interest in diagnostic laboratory methods and imaging of Cushing disease, outcomes of therapy of various pituitary tumors including acromegaly and prolactinomas, as well as studies on growth hormone secretion in aging. She served as Pituitary-adrenal-gonad core group chair at Mayo Clinic and has been involved with training of clinical endocrine fellows over the years. Dr. Erickson received her medical degree from Comenius University, Slovakia. She has completed both her medical residency and fellowship in Endocrinology, Metabolism and Nutrition at Mayo Clinic, Rochester. She is a member of Endocrine Society, Pituitary Society, AACE and over the years active member of various committees of Women in Endocrinology. Dr. Erickson is also a member of the Clinical Endocrinology Update Steering Committee.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss indications of Cosyntropin stimulation test interpretation and its limitations for diagnosis of secondary adrenal insufficiency
  • Review testing for secondary adrenal insufficiency via Metyrapone testing, Insulin tolerance test or simple DHEAs measurement.
Does When You Eat Matter for Weight Management?
Available:
SEPTEMBER 10
Krista Varady, PhD
University of Illinois, Chicago, Chicago, Illinois, USA
Krista Varady, PhD, is a Professor of Nutrition at the University of Illinois, Chicago. Her research focuses on the efficacy of intermittent fasting for weight loss, weight maintenance, and cardio-protection in obese adults. Her work is funded by the NIH, American Heart Association, International Life Sciences Institute, and the University of Illinois. She has published over 70 publications on this topic and is also the author of a book for the general public, the "Every Other Day Diet."

Disclosures:

Research Funding: American Heart Association; International Life Sciences Institute; National Institutes of Health (NIDDK R01DK110783, NHLBI, R01HL148661); Nestle Health Sciences
Conflict of Interest: Received author fees from Hachette for “Every Other Day Diet”
 

Learning Objectives:

  • Explain the impact of circadian rhythms and their disruption on body weight regulation
  • Define time restricted eating and describe the impact of time restricted eating on weight management
  • Discuss the different forms of intermittent fasting and their effects on weight and metabolism.
Drug Effects on Thyroid Function
Available:
SEPTEMBER 10
James V. Hennessey, MD
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
James V. Hennessey, MD, is an Associate Professor of Medicine at Harvard Medical School and Director of Clinical Endocrinology at Beth Israel Deaconess Medical Center. He received his degree from the University of Graz in Austria and completed his residency at the Hospital of Central Connecticut. His clinical interests include thyroid, pituitary, and adrenal disorders.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify drugs that interfere with thyroid hormone therapy
  • Discuss data regarding drugs that interfere with thyroid function laboratory tests
  • Summarize current medical knowledge regarding drugs that interfere with endogenous thyroid function.
Evaluation and Management of Early Menopause
Not Currently Available
Kathryn A. Martin, MD(Speaker)
Massachusetts General Hospital, Boston, Massachusetts, USA
Kathryn A. Martin, MD, is an Assistant Professor of Medicine at Harvard Medical School and practicing clinician in the Reproductive Endocrine Unit at Massachusetts General Hospital. She obtained her MD from Dartmouth Medical School and completed her internship and residency in Internal Medicine at Emory University Affiliated Hospitals, followed by a clinical and research fellowship in Endocrinology at Massachusetts General Hospital. Her clinical research interests are in the area of female reproduction and her primary clinical area of expertise is in the area of the evaluation and management of menopausal symptoms. Dr. Martin served on the ABIM Subspecialty Board in Endocrinology for six years and was Chair of both the Special Programs Committee and the Clinical Guidelines Subcommittee at the Endocrine Society. She is currently serving as a member of the ES Board Review Committee. Dr. Martin is also the Senior Physician Editor for Endocrinology and Patient Education at UpToDate, an online clinical reference for physicians.

Disclosures:

Physician Editor: UpToDate
Bradley D. Anawalt, MD(Moderator)
University of Washington, Seattle, Washington, USA
Bradley D. Anawalt, MD, is the Chief of Medicine at the University of Washington Medical Center and Professor and Vice Chair of the Department of Medicine at the University of Washington. He earned his bachelor's degree in anthropology at the University of Santa Clara and his medical degree at the University of California at Davis. Dr. Anawalt completed his internal medicine residency at the University of Washington in 1992 and served as chief resident at the Seattle VA Medical Center 1992-1993. He completed a fellowship in endocrinology at the University of Washington and joined the faculty in 1995. Dr. Anawalt's teaching has been recognized with the Paul Beeson teaching award and the endocrine-fellowship teaching award at the University of Washington. In addition to serving as the North American Editor for Clinical Endocrinology, he serves as a consultant to the United States Anti-Doping Agency, is on the editorial board of the Journal of Clinical Endocrinology and Metabolism and served as an Associate Editor of Endocrine Reviews. He also writes questions for the American Board of Internal Medicine self-evaluation program (for board re-certification). He has done research in male infertility, male hormonal contraception and the male reproductive physiology. He lives in Seattle with his wife and three daughters.

Disclosures:

Other: Author of chapters for UpToDate
 

Learning Objectives:

  • Describe the diagnostic evaluation of premature menopause and early menopause
  • Identify the best hormonal therapy regimens for women with early menopause
  • Describe the non-hormonal management of early menopause.
Helping Our Patients Change Behavior Using the Science of Habit Formation
Available:
SEPTEMBER 10
Robert F. Kushner, MD
Northwestern University, Evanston, Illinois, USA
Robert F. Kushner, MD, is a Professor of Medicine and Medical Education at the Feinburg School of Medicine at Northwestern University and Medical Director of the Wellness Institute at Northwestern Memorial Hospital in Chicago. He received his doctorate from the University of Illinois at Chicago and completed his residency at the McGaw Medical Center at Northwestern Memorial Hospital. Dr. Kushner has authored over 200 original articles, books, and book chapters covering on medical nutrition and obesity.

Disclosures:

Advisory Board: Novo Nordisk; WW (formally Weight Watchers)
Research Support: Novo Nordisk
 

Learning Objectives:

  • Define the guiding principles and theories of behavior change and habit formation
  • Describe the key components of cognitive behavioral treatment and motivational interviewing
  • Discuss practical approaches to support behavior change in the office setting.
Highlights of the Management of Transwomen from Adolescence Through Early Adulthood
Available:
SEPTEMBER 10
Ximena Lopez, MD
UT Southwestern Medical Center, Dallas, Texas, USA
Ximena Lopez, MD, did her residency in Pediatrics at the University of Illinois at Chicago, IL, and her fellowship in Pediatric Endocrinology at Massachusetts General Hospital/Harvard Medical School, Boston, MA. She is currently the Medical Director for the GENder, Education and Care Interdisciplinary Support (GENECIS) program, which provides mental health and endocrine care for gender non-conforming children and adolescents. Dr. Lopez is also currently co-chair of the Transgender Health Special Interest Group of the Pediatric Endocrine Society.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Summarize the rationale and the benefits of risks of hormone-congruent therapy initiated early in puberty for transwomen
  • Identify, initiate and manage safe and effective hormone-congruent regimens for transwomen
  • Describe approaches on the preservation of fertility and long term optimization of cardiovascular and bone health.
Hypercalcemia: Common Causes, Rare Causes, and Management
Available:
SEPTEMBER 10
Thomas J. Weber, MD
Duke University Medical Center, Durham, North Carolina, USA
Thomas J. Weber, MD, is an Associate Professor of Medicine at Duke University Medical Center, where he is Medical Director of the Duke Clinical Bone Laboratory, and a Clinical Investigator in the Clinical Research Training Program of the Duke University School of Medicine. He is also a permanent member of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA, and a member of the Peer Review Committee for the Endocrine Society Self-Assessment Program (ESAP). Dr. Weber has also authored the chapters on “Osteoporosis” and “Approach to the Patient with Metabolic Bone Disease” in the 25th and 26th editions of Cecil’s Textbook of Medicine. Dr. Weber attended the University of Chicago-Pritzker medical school, and thereafter completed his internship and residency training in Internal Medicine at Yale-New Haven Hospital and a research fellowship in Endocrinology at Duke University Medical Center. His research focuses on metabolic bone disease more broadly, including the hypophosphatemic, osteomalacic disorders X-linked hypophosphatemic rickets (XLH) and tumor-induced osteomalacia, as well as clinical and translational studies of osteoporosis and primary hyperparathyroidism.

Disclosures:

Editorial Consultant: Elsevier; MedIQ
Consultant/Travel Support: Pharmacosmos
Research Support/Consultant/Travel Support: Ultragenyx
The Endocrine Society - Member, Endocrine Self-Assessment Program Faculty Peer Review Committee;
Food and Drug Administration - Permanent member, Endocrine and Metabolic Drug Advisory Committee (EMDAC)
 

Learning Objectives:

  • Discuss the etiology of hypercalcemic disorders, a common referral question for Endocrinologists
  • Identify flags that indicate an unusual cause and when further testing is indicated
  • Utilize medications and surgical referrals effectively for hypercalcemia.
Hyperprolactinemia: Differential Diagnosis
Not Currently Available
Shlomo Melmed, MB ChB(Speaker)
Cedars-Sinai Medical Center, Los Angeles, California, USA
Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).

Disclosures:

No relevant financial relationships.
Monica Gadelha, MD, PhD(Moderator)
Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
Monica Gadelha, MD, PhD, a member of the Brazilian National Academy of Medicine, is Professor of Endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro (UFRJ) and directs the Neuroendocrine Research Center at Hospital Universitário Clementino Fraga Filho of the UFRJ. Dra Gadelha also heads the Neuroendocrine Section and the Molecular Genetics Laboratory of the Instituto Estadual do Cérebro Paulo Niemeyer. She is a board member of the Department of Neuroendocrinology at the Brazilian Society of Endocrinology and Metabolism, as well as a researcher at Brazil’s Conselho Nacional de Desenvolvimento Cientifico e Tecnológico. She graduated at the UFRJ and performed the research and experimental part of her PhD at the University of Illinois at Chicago, IL, USA, receiving her PhD from the UFRJ. Major research interests include the molecular pathogenesis, diagnosis, and treatment of pituitary tumours. Dra Gadelha has published more than 120 peer-reviewed journal articles and book chapters and has served on the editorial boards and as a referee of several international journals.

Disclosures:

Advisory Board: Crinectics; Novartis
Research Investigator: Crinectics; Novartis
Speaker: Ipsen; Novartis
 

Learning Objectives:

  • Review the differential diagnosis of hyperprolactinemia
  • Discuss the main causes
  • Discuss whether PRL receptor mutation is really a cause of hyperprolactinemia. Should we consider this diagnosis? When?
Hypertriglyceridemia and Cardiovascular Disease: To Treat or Not to Treat?
Available:
SEPTEMBER 10
Savitha Subramanian, MD
University of Washington, Seattle, Washington, USA
Savitha Subramanian, MD, is an Associate Professor of Medicine and Metabolism, Endocrinology and Nutrition at the University of Washington Endocrine and physician at the Diabetes Care Center at University of Washington Medical Center-Roosevelt. She received her degree from Stanley Medical College in India and completed her residency at the University of Illinois College of Medicine.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Define Hypertriglyceridemia and explain evidence for the role of triglyceride rich lipoproteins in the development of atherosclerosis
  • Describe efficacy and safety in CVD outcome trials of triglyceride lowering drugs, including omega-3 fatty acids
  • Identify which patients might benefit from the addition of omega-3 fatty acids or fibrates to statin therapy
  • Discuss benefits and risks of omega-3 fatty acids in patients with type 2 diabetes.
Inpatient Diabetes Management
Not Currently Available
Rita R. Kalyani, MD, MHS(Speaker)
Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Rita R. Kalyani, MD, MHS, is an Associate Professor of Medicine at Johns Hopkins School of Medicine, Core Faculty at the Johns Hopkins Center on Aging and Health, and Associate Faculty at the Welch Center for Prevention, Epidemiology, and Clinical Research. She also directs the Diabetes Management Service for Johns Hopkins’ Total Pancreatectomy Islet Auto Transplant Program and is the co-founder and Editor-in-Chief of the Johns Hopkins Diabetes Guide for healthcare professionals. Dr. Kalyani has a life-long association with Johns Hopkins University, having and completed her medical degree, residency, and fellowship at there. She also obtained a Masters in Health Science in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health.
Dr. Kalyani’s research focuses on diabetes and aging and investigates accelerated muscle loss, disability, and frailty in older adults with diabetes. Other research interests include sex differences in diabetes and heart disease and physical functioning in other endocrine and metabolic diseases.

Disclosures:

No relevant financial relationships.
Cecilia Low Wang, MD(Moderator)
University Colorado Anschutz Med Campus / School of Medicine, Aurora, Colorado, USA
Cecilia Low Wang, MD, is an Endocrinologist and Professor of Medicine at the University of Colorado Anschutz Medical Campus School of Medicine, in the Division of Endocrinology, Metabolism and Diabetes, as well as Lead Clinician-Scientist at CPC Clinical Research, an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. She is the Director of the Glucose Management Team at the University of Colorado Hospital, and Director for Housestaff and Medical Student Education for the Division of Endocrinology. Dr. Low Wang attended Pomona College and earned her medical degree from the University of Rochester School of Medicine. She completed her internship and residency at the University of Utah Health Sciences Center where she also served as Chief Medical Resident. After housestaff training, she did a clinical and research fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado School of Medicine investigating insulin action in the vascular wall with a focus on vascular smooth muscle cells, and mechanisms of atherosclerosis in diabetes.

Disclosures:

Advisory Board: BioMarin Pharmaceutical Inc.; CSL Behring GMBH
Research Investigator: Novo Nordisk; uniQure
Other: Employee at CPC Clinical Research
 

Learning Objectives:

  • Outline key information from the most recent available data for hyperglycemic emergencies
  • Propose practical strategies for initial and ongoing anti-hyperglycemia management for specific situations in the inpatient setting such as high dose glucocorticoid use, transitioning off intravenous insulin infusion, and enteral and parenteral nutrition
  • Discuss approaches to addressing diabetes technology use in hospitalized patients on insulin pumps and/or hybrid-closed-loop systems.
Insulin Therapy: Analogues, Concentrated Insulins, and Inhaled Insulins
Available:
SEPTEMBER 10
M. Sue Kirkman, MD
University of North Carolina, Chapel Hill, North Carolina, USA
M. Sue Kirkman, MD, is the medical director of the UNC Diabetes Care Center’s Clinical Trials Unit, which consists of five investigators, five study coordinators, and three research assistants conducting 15-20 trials in type 1 and type 2 diabetes and in obesity. Dr. Kirkman is site principal investigator of several clinical trials including the NIDDK-funded GRADE study, for which she also serves as co-chair of the Outcomes Committee. She is also co-PI of a CDC-funded grant to better distinguish between type 1 and type 2 diabetes in adults using EHR and survey data. In addition to her clinical practice and research work, Dr. Kirkman is currently chair of the National Diabetes Education Program (NDEP), a joint initiative of NIDDK and the CDC.

Disclosures:

Research Investigator: Bayer; Novo Nordisk
 

Learning Objectives:

  • Summarize the pharmacokinetic and pharmacodynamic differences among the available insulins
  • Describe an approach to individualizing selection of insulin analogue therapy using cases
  • Evaluate the need for use of concentrated insulin therapy using cases.
LYUMJEV™ (insulin lispro-aabc) Injection
Not Currently Available
Live Product Theater with Q&A
Thomas C. Blevins, MD
Texas Diabetes and Endocrinology, Austin, Texas, USA
Thomas C. Blevins, MD, is an endocrinologist in private practice at Texas Diabetes and Endocrinology in Austin. Dr. Blevins received his medical degree from Baylor College of Medicine in Houston, Texas, where he also completed an internship and residency in medicine and a fellowship in endocrinology and metabolism. He is board certified in lipidology and internal medicine, with a subspecialty certification in endocrinology and metabolism. Dr. Blevins is a Fellow of the American Association of Clinical Endocrinologists and the National Lipid Association. He has been involved in several diabetes-related clinical trials.
sponsored by:
Lilly Diabetes
Management of Hypoparathyroidism
Available:
SEPTEMBER 10
Dolores M. Shoback, MD
University of California, San Francisco School of Medicine, San Francisco, California, USA
Dolores M. Shoback, MD, is Professor of Medicine and Associate Program Director of the Fellowship Program in Diabetes, Endocrinology and Metabolism at the University of California, San Francisco School of Medicine. She attended the University of Pennsylvania and obtained her MD from Johns Hopkins University School of Medicine. She completed Internal Medicine residency at Johns Hopkins Hospital and her fellowship in Endocrinology and Hypertension at the Brigham and Women’s Hospital/Harvard Medical School, where she developed career-long interests in endocrine hypertension, metabolic bone disease and parathyroid disorders. Dr. Shoback is active in basic and clinical research involving calcium-sensing receptors and parathyroid disorders.

Disclosures:

Investigator: NPS (Shire, Takeda)- sponsored clinical trial REPLACE on use of PTH (1-84) in adults with hypoparathyroidism
Consultant: Ascendis Pharmaceuticals; Bridge Bio; Shire
 

Learning Objectives:

  • Identify patients with hypoparathyroidism and understand the etiologies
  • Select patients who may be appropriate candidates for newer therapies
  • Recognize when genetic testing for hypocalcemic disorders is indicated.
Management of Medullary Thyroid Cancer
Not Currently Available
Michael W. Yeh, MD(Speaker)
UCLA, Los Angeles, California, USA
Michael W. Yeh, MD, is Founder and Director of the Endocrine Surgery Program and Assistant Professor at UCLA. After pursuing his studies at Stanford University and Harvard Medical School, Dr. Yeh trained in general surgery at UC San Francisco. He then completed the prestigious T.S. Reeve International Fellowship in endocrine surgery at the Royal North Shore Hospital in Sydney, Australia. Dr. Yeh is an expert in minimally invasive parathyroid surgery, thyroid cancer, and adrenal tumors, including pheochromocytoma and adrenocortical carcinoma. He has published more than 100 scholarly articles and book chapters on these topics.

Disclosures:

No relevant financial relationships.
Elizabeth N. Pearce, MD, MSc(Moderator)
Boston University Medical Center, Boston, Massachusetts, USA
Elizabeth N. Pearce, MD, received her undergraduate and medical degrees from Harvard and a masters’ degree in epidemiology from the Boston University School of Public Health. She completed her residency in internal medicine at Beth Israel Deaconess Medical Center, and her fellowship in endocrinology at Boston University. She is a Professor of Medicine at Boston University School of Medicine in the Section of Endocrinology, Diabetes, and Nutrition. She is the current President of the American Thyroid Association. She also serves as the Regional Coordinator for North America for the Iodine Global Network. She has served on multiple editorial boards, including those for Endocrine Practice, Thyroid, the Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, and Lancet Diabetes & Endocrinology. She recently co-chaired the American Thyroid Association’s Thyroid in Pregnancy Guidelines Task Force. Her research interests include the sufficiency of dietary iodine in the U.S., thyroid function in pregnancy, the thyroid effects of environmental perchlorate exposure, and the cardiovascular effects of subclinical thyroid dysfunction. Dr. Pearce was the 2011 recipient of the American Thyroid Association’s Van Meter Award for outstanding contributions to research on the thyroid gland.

Disclosures:

Other: Immediate Past President and member of Board of Directors at American Thyroid Association; Associate Editor of Journal at American Association of Clinical Endocrinologists; member of Management Council at Iodine Global Network
 

Learning Objectives:

  • Identify considerations surrounding initial diagnosis and genetic testing in medullary thyroid cancer
  • Determine the appropriate initial therapy and postoperative surveillance for medullary cancer patients
  • Identify patients with advanced and metastatic medullary cancer who are appropriate candidates for directed therapies and systemic therapies.
Management of Thyroid Disorders in Lactation
Not Currently Available
Angela M. Leung, MD(Speaker)
UCLA David Geffen School of Medicine, Los Angeles, California, USA
Angela M. Leung, MD, is an Associate Professor of Medicine at the UCLA David Geffen School of Medicine and an endocrinologist at both UCLA and the VA Greater Los Angeles Healthcare System. After pursuing her undergraduate studies at Occidental College, Dr. Leung completed her internal medicine residency and endocrinology fellowship training at Boston University School of Medicine. She also studied at the Boston University School of Public Health and obtained a master's degree in epidemiology. Dr. Leung has clinical and research interests in thyroid disorders and she also sees patients regarding parathyroid and adrenal disorders. She has published widely and lectures frequently on thyroid disease, including hyperthyroidism, hypothyroidism, thyroid nodules, thyroid cancer, and thyroid disease during pregnancy.

Disclosures:

Editorial Board and Editor: American Thyroid Association
Elizabeth N. Pearce, MD, MSc(Moderator)
Boston University Medical Center, Boston, Massachusetts, USA
Elizabeth N. Pearce, MD, received her undergraduate and medical degrees from Harvard and a masters’ degree in epidemiology from the Boston University School of Public Health. She completed her residency in internal medicine at Beth Israel Deaconess Medical Center, and her fellowship in endocrinology at Boston University. She is a Professor of Medicine at Boston University School of Medicine in the Section of Endocrinology, Diabetes, and Nutrition. She is the current President of the American Thyroid Association. She also serves as the Regional Coordinator for North America for the Iodine Global Network. She has served on multiple editorial boards, including those for Endocrine Practice, Thyroid, the Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, and Lancet Diabetes & Endocrinology. She recently co-chaired the American Thyroid Association’s Thyroid in Pregnancy Guidelines Task Force. Her research interests include the sufficiency of dietary iodine in the U.S., thyroid function in pregnancy, the thyroid effects of environmental perchlorate exposure, and the cardiovascular effects of subclinical thyroid dysfunction. Dr. Pearce was the 2011 recipient of the American Thyroid Association’s Van Meter Award for outstanding contributions to research on the thyroid gland.

Disclosures:

Other: Immediate Past President and member of Board of Directors at American Thyroid Association; Associate Editor of Journal at American Association of Clinical Endocrinologists; member of Management Council at Iodine Global Network
 

Learning Objectives:

  • Evaluate evidence for the safety of anti-thyroid drugs in lactating women with Graves' disease
  • Discuss safety considerations regarding iodine therapy or scanning relative in women who are breastfeeding or who have recently stopped breastfeeding
  • Describe the importance of adequate iodine nutrition in lactation.
Management of Transmen Beyond Gender Congruency: Bone Health, Cardiovascular Health, and Fertility
Not Currently Available
Richard A. Bebb, MD(Speaker)
University of British Columbia, Vancouver, British Columbia, Canada
Richard A. Bebb, MD, is an endocrinologist at St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia. He is a consultant endocrinologist with research and clinical interests in disorders of male gonadal function and reproduction and a Clinical Associate Professor at the University of British Columbia.

Disclosures:

No relevant financial relationships.
Bradley D. Anawalt, MD(Moderator)
University of Washington, Seattle, Washington, USA
Bradley D. Anawalt, MD, is the Chief of Medicine at the University of Washington Medical Center and Professor and Vice Chair of the Department of Medicine at the University of Washington. He earned his bachelor's degree in anthropology at the University of Santa Clara and his medical degree at the University of California at Davis. Dr. Anawalt completed his internal medicine residency at the University of Washington in 1992 and served as chief resident at the Seattle VA Medical Center 1992-1993. He completed a fellowship in endocrinology at the University of Washington and joined the faculty in 1995. Dr. Anawalt's teaching has been recognized with the Paul Beeson teaching award and the endocrine-fellowship teaching award at the University of Washington. In addition to serving as the North American Editor for Clinical Endocrinology, he serves as a consultant to the United States Anti-Doping Agency, is on the editorial board of the Journal of Clinical Endocrinology and Metabolism and served as an Associate Editor of Endocrine Reviews. He also writes questions for the American Board of Internal Medicine self-evaluation program (for board re-certification). He has done research in male infertility, male hormonal contraception and the male reproductive physiology. He lives in Seattle with his wife and three daughters.

Disclosures:

Other: Author of chapters for UpToDate
 

Learning Objectives:

  • Describe the optimization of gender-congruent hormone therapy for transmen
  • Identify necessary long term safety monitoring and approaches to optimization of cardiovascular risk
  • Identify approaches to long term fertility management.
Master Clinician: Challenges of Suspicious Adrenal Masses
Not Currently Available
Irina Bancos, MD(Moderator)
Mayo Clinic, Rochester, Minnesota, USA
Irina Bancos, MD, is an Associate Professor of Medicine and adrenal endocrinologist at the Mayo Clinic in Rochester, Minnesota. She received her MD from the Iuliu Hațieganu University of Medicine and Pharmacy in Romania and completed her residency in Internal Medicine at Danbury Hospital in Connecticut. She received the 2017 and 2020 Teacher of the Year Awards in Endocrinology from the Mayo Fellows' Association.

Disclosures:

Consultant: ClinCor; Corcept Therapeutics; HRA Pharma
Richard Auchus, MD, PhD(Panelist)
University of Michigan, Ann Arbor, Michigan, USA
Richard J. Auchus, MD, PhD, is a Professor of Internal Medicine, Division of Metabolism, Endocrinology & Diabetes (MEND) and director of the MEND Fellowship Program. He received his medical degree and PhD in pharmacology from Washington University in St. Louis and completed a residency at the University of Iowa and an endocrinology fellowship at UTHSC-San Antonio/Wilford Hall Medical Center. Dr. Auchus is a steroid biologist with expertise both in basic science and clinical/translational science. His work has included translational research into molecular and genetic mechanisms of human hypertension, improved diagnostic studies and management in primary aldosteronism and Cushing syndromes, modifier genes in 21-hydroxylase deficiency, cardiovascular disease in polycystic ovary syndrome, and the endocrinology of traumatic brain injury.

Disclosures:

Consultant: Adrenas Therapeutics; Corcept Therapeutics; Janssen Pharmaceuticals; Novartis Pharmaceuticals; Quest Diagnostics; Strongbridge Biopharma
Contracted Research: Corcept Therapeutics; Neurocrine Biosciences; Novartis Pharmaceuticals; Spruce Biosciences
Travis J. McKenzie, MD(Panelist)
Mayo Clinic, Rochester, Minnesota, USA
Travis. J. McKenzie, MD, is an Associate Professor of Medicine and endocrine and metabolic surgeon at the Mayo Clinic in Rochester, Minnesota. He received his MD from the Tufts University and completed his residency at the Mayo Clinic, followed by fellowships at Massachusetts General Hospital and Brigham and Women’s Hospital. He has received multiple Teacher of the Year awards from the Mayo Clinic and was inducted into their Teaching Hall of Fame in 2017.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss the role of diagnostic tests including imaging characteristics, hormonal evaluation and novel methods (steroid metabolomics) in setting of suspicious adrenal masses from standpoint of endocrinologist and surgeon
  • Explain the indications and shortcomings of performance of adrenal biopsy in suspicious adrenal mass from endocrine and surgical standpoint
  • Recognize important factors which determine particular surgical approach to adrenal mass from surgical perspective.
Master Clinician: Implementing Current Guidelines for T2D
Not Currently Available
Serena Cardillo, MD(Moderator)
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Serena Cardillo, MD, is a Professor of Clinical Medicine in the Division of Endocrinology, Diabetes & Metabolism in the Perelman School of Medicine at The University of Pennsylvania, where she also completed her training in internal medicine and endocrinology. Dr. Cardillo’s clinical practice is based at the Penn Rodebaugh Diabetes Center where she serves as the Director of Graduate Diabetes Education. Her clinical interests are in type 1 and type 2 diabetes, cystic fibrosis related diabetes and post-transplant diabetes. She is also an Associate Program Director and Core Faculty Member in Endocrinology for the Internal Medicine Residency Program. Her interests in graduate medical education are in ambulatory subspecialty education and the use of simulation to assess and teach communication skills. At the postgraduate level she has led several innovative national education programs in the area of diabetes management for primary care providers. Her work has been recognized in institutional teaching awards and selection as a Philadelphia Magazine Top Doctor Award in 2018.

Disclosures:

No relevant financial relationships.
Jennifer B. Green, MD(Panelist)
Duke University, Durham, North Carolina, USA
Jennifer B. Green, MD, is a Professor of Medicine in Endocrinology, Metabolism, and Nutrition at Duke University and a faculty member of the Duke Clinical Research Institute. She received her doctorate from University of Virginia and completed her residency at the University of North Carolina at Chapel Hill. Dr. Green served as chief of the Endocrinology section at the Durham VA Medical Center from 2003-2017. Her clinical and research interests focus on strategies to predict, prevent, and treat diabetes mellitus and its complications.

Disclosures:

Research Support: Boehringer Ingelheim; NIDDK; Sanofi/Lexicon
Consultant: AstraZeneca; Boehringer Ingelheim/Lilly Alliance; Novo Nordisk
Rita R. Kalyani, MD, MHS(Panelist)
Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Rita R. Kalyani, MD, MHS, is an Associate Professor of Medicine at Johns Hopkins School of Medicine, Core Faculty at the Johns Hopkins Center on Aging and Health, and Associate Faculty at the Welch Center for Prevention, Epidemiology, and Clinical Research. She also directs the Diabetes Management Service for Johns Hopkins’ Total Pancreatectomy Islet Auto Transplant Program and is the co-founder and Editor-in-Chief of the Johns Hopkins Diabetes Guide for healthcare professionals. Dr. Kalyani has a life-long association with Johns Hopkins University, having and completed her medical degree, residency, and fellowship at there. She also obtained a Masters in Health Science in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health.
Dr. Kalyani’s research focuses on diabetes and aging and investigates accelerated muscle loss, disability, and frailty in older adults with diabetes. Other research interests include sex differences in diabetes and heart disease and physical functioning in other endocrine and metabolic diseases.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Prescribe and monitor diabetes pharmacotherapies for patients with significant comorbidities and/or complications
  • Recognize specific clinical situations in which best available evidence supports use of certain diabetes agents over others
  • Apply principles discussed in this session to modify medication regimens and implement strategies to minimize risk of hypoglycemia in older adults with diabetes.
Master Clinician: Management of Low Serum Testosterone Concentrations in Men 65 and Older
Not Currently Available
Bradley D. Anawalt, MD(Moderator)
University of Washington, Seattle, Washington, USA
Bradley D. Anawalt, MD, is the Chief of Medicine at the University of Washington Medical Center and Professor and Vice Chair of the Department of Medicine at the University of Washington. He earned his bachelor's degree in anthropology at the University of Santa Clara and his medical degree at the University of California at Davis. Dr. Anawalt completed his internal medicine residency at the University of Washington in 1992 and served as chief resident at the Seattle VA Medical Center 1992-1993. He completed a fellowship in endocrinology at the University of Washington and joined the faculty in 1995. Dr. Anawalt's teaching has been recognized with the Paul Beeson teaching award and the endocrine-fellowship teaching award at the University of Washington. In addition to serving as the North American Editor for Clinical Endocrinology, he serves as a consultant to the United States Anti-Doping Agency, is on the editorial board of the Journal of Clinical Endocrinology and Metabolism and served as an Associate Editor of Endocrine Reviews. He also writes questions for the American Board of Internal Medicine self-evaluation program (for board re-certification). He has done research in male infertility, male hormonal contraception and the male reproductive physiology. He lives in Seattle with his wife and three daughters.

Disclosures:

Other: Author of chapters for UpToDate
Richard A. Bebb, MD(Panelist)
University of British Columbia, Vancouver, British Columbia, Canada
Richard A. Bebb, MD, is an endocrinologist at St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia. He is a consultant endocrinologist with research and clinical interests in disorders of male gonadal function and reproduction and a Clinical Associate Professor at the University of British Columbia.

Disclosures:

No relevant financial relationships.
Alvin M. Matsumoto, MD(Panelist)
University of Washington, Seattle, Washington, USA
Alvin M. Matsumoto, MD, directs, serves as an attending and sees patients in the GRECC Osteoporosis & Andrology Clinic, a multi-disciplinary subspecialty referral clinic for the evaluation and treatment of patients with osteoporosis and other metabolic bone disease and male hypogonadism. He also serves as an attending physician, sees patients, and teaches residents and medical students on the Geriatrics House Staff Service of Community Living Center/Transitional Care Unit at the VA Puget Sound Health Care System. Dr. Matsumoto directs the VA Special Fellowship Program in Advanced Geriatrics, a fellowship for research training in gerontology, geriatric medicine and geriatric psychiatry. Dr. Matsumoto’s research program examines the physiological and clinical effects and mechanisms of action of androgens and their active metabolites in young and aging men. Specifically, his multi-disciplinary and collaborative research program investigates androgen effects on body composition (fat mass, lean mass and bone mineral density), muscle mass and strength, metabolic function, prostate gland and cardiovascular disease, pituitary gonadotropin secretion, spermatogenesis, sexual function, cognitive function, mood and quality of life.

Disclosures:

Research Support: AbbVie
Royalty: UpToDate (Klinefelter Syndrome)
Co-Chair: Partnership for the Accurate Testing of Hormones (PATH)
 

Learning Objectives:

  • Identify how to make the diagnosis of male hypogonadism in older men
  • Identify the relative benefits and risks of testosterone replacement therapies in older men with low serum testosterone
  • Describe how to manage male hypogonadism in older men with relative contraindications to testosterone therapy.
Master Clinician: Osteoporosis Challenges in Treatment
Not Currently Available
Dolores M. Shoback, MD(Moderator)
University of California, San Francisco School of Medicine, San Francisco, California, USA
Dolores M. Shoback, MD, is Professor of Medicine and Associate Program Director of the Fellowship Program in Diabetes, Endocrinology and Metabolism at the University of California, San Francisco School of Medicine. She attended the University of Pennsylvania and obtained her MD from Johns Hopkins University School of Medicine. She completed Internal Medicine residency at Johns Hopkins Hospital and her fellowship in Endocrinology and Hypertension at the Brigham and Women’s Hospital/Harvard Medical School, where she developed career-long interests in endocrine hypertension, metabolic bone disease and parathyroid disorders. Dr. Shoback is active in basic and clinical research involving calcium-sensing receptors and parathyroid disorders.

Disclosures:

No relevant financial relationships.
E. Michael Lewiecki, MD(Panelist)
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA
E. Michael Lewiecki, MD, is Director of New Mexico Clinical Research & Osteoporosis Center and Clinical Assistant Professor of Medicine at University of New Mexico Health Sciences Center. He received his doctorate from Northwestern University Medical School and completed his postgraduate medical training at University of New Mexico Health Sciences Center. Dr. Lewiecki is currently a consultant in osteoporosis and metabolic bone disease, supervisor of bone densitometry at his center and principal investigator for their osteoporosis clinical trials, and an educator with a special interest in the management of osteoporosis and metabolic bone disease. Dr. Lewiecki is past president of the International Society for Clinical Densitometry (ISCD) and a board member of the ISCD and the National Osteoporosis Foundation. He is founding president of the Osteoporosis Foundation of New Mexico and program director of its flagship activity, the annual Santa Fe Bone Symposium. He is founder and Director of Bone Health TeleECHO (Extension for Community Healthcare Outcomes), an ongoing telementoring program for healthcare professionals focusing on osteoporosis and metabolic bone diseases.

Disclosures:

Employed by New Mexico Clinical Research & Osteoporosis Center, which has received the following in the past one year: 1) Institutional Research Grant Support
Thomas J. Weber, MD(Panelist)
Duke University Medical Center, Durham, North Carolina, USA
Thomas J. Weber, MD, is an Associate Professor of Medicine at Duke University Medical Center, where he is Medical Director of the Duke Clinical Bone Laboratory, and a Clinical Investigator in the Clinical Research Training Program of the Duke University School of Medicine. He is also a permanent member of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA, and a member of the Peer Review Committee for the Endocrine Society Self-Assessment Program (ESAP). Dr. Weber has also authored the chapters on “Osteoporosis” and “Approach to the Patient with Metabolic Bone Disease” in the 25th and 26th editions of Cecil’s Textbook of Medicine. Dr. Weber attended the University of Chicago-Pritzker medical school, and thereafter completed his internship and residency training in Internal Medicine at Yale-New Haven Hospital and a research fellowship in Endocrinology at Duke University Medical Center. His research focuses on metabolic bone disease more broadly, including the hypophosphatemic, osteomalacic disorders X-linked hypophosphatemic rickets (XLH) and tumor-induced osteomalacia, as well as clinical and translational studies of osteoporosis and primary hyperparathyroidism.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Determine optimal osteoporosis treatment based on patient characteristics
  • Select patients for drug holidays and treatment discontinuations to minimize bone density loss and subsequent fractures
  • Describe how to manage the patient with atypical femoral fracture.
Medical Treatment of Cushing Disease
Available:
SEPTEMBER 10
Eliza B. Geer, MD
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Eliza B. Geer, MD, joined the faculty at The Mount Sinai Medical Center in July, 2006 with an appointment in the Division of Endocrinology and a secondary appointment in the Department of Neurosurgery. After graduating from Columbia University, she attended Mount Sinai School of Medicine, graduating with Distinction in Research. She completed her Internship and Residency in Internal Medicine at Columbia Presbyterian Medical Center, where she became involved in neuroendocrine research, conducting studies on the hypothalamic-pituitary-adrenal axis and acromegaly. After completing her residency, she conducted a year of clinical research at Columbia's Obesity Research Center, funded by a NIH T32 grant, where she focused on body composition and appetite in acromegaly. She then completed a fellowship in Endocrinology, Diabetes and Bone Disease at the Mount Sinai Medical Center, graduating in 2006.

Disclosures:

Research Investigator: Bristol-Myers Squibb; Chiasma; Corcept; Ionis; Novartis; Strongbridge
 

Learning Objectives:

  • Differentiate between treatment options for patients with Cushing’s disease not in remission after surgery: medical therapy X bilateral adrenalectomy
  • medical treatment X radiotherapy
  • Evaluate indications, risks, benefits and biomarkers of available medical therapies
  • Describe the new drugs in the horizon.
MYCAPSSA® (octreotide) Delayed-Release Oral Capsules: A New Option for Appropriate Patients with Acromegaly
Product Theater Presentation
Anthony Heaney, MD, PhD
University of California-Los Angeles, Los Angeles, California, USA
Dr. Heaney is a Professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). His primary areas of clinical and research interest involve the pathogenesis of pituitary tumors and exploiting novel molecular targets to develop innovative treatments for pituitary tumors, and other neuroendocrine tumors. Dr. Heaney has published extensively.

Disclosures:

N/A - No CME credits
Not Currently Available
Live Product Theater with Q&A
Anthony Heaney, MD, PhD
University of California-Los Angeles, Los Angeles, California, USA
Dr. Heaney is a Professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). His primary areas of clinical and research interest involve the pathogenesis of pituitary tumors and exploiting novel molecular targets to develop innovative treatments for pituitary tumors, and other neuroendocrine tumors. Dr. Heaney has published extensively.

Disclosures:

N/A - No CME credits
sponsored by:
Chiasma, Inc.
Osteoporosis Medication: Timing is Everything
Available:
SEPTEMBER 10
E. Michael Lewiecki, MD
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA
E. Michael Lewiecki, MD, is Director of New Mexico Clinical Research & Osteoporosis Center and Clinical Assistant Professor of Medicine at University of New Mexico Health Sciences Center. He received his doctorate from Northwestern University Medical School and completed his postgraduate medical training at University of New Mexico Health Sciences Center. Dr. Lewiecki is currently a consultant in osteoporosis and metabolic bone disease, supervisor of bone densitometry at his center and principal investigator for their osteoporosis clinical trials, and an educator with a special interest in the management of osteoporosis and metabolic bone disease. Dr. Lewiecki is past president of the International Society for Clinical Densitometry (ISCD) and a board member of the ISCD and the National Osteoporosis Foundation. He is founding president of the Osteoporosis Foundation of New Mexico and program director of its flagship activity, the annual Santa Fe Bone Symposium. He is founder and Director of Bone Health TeleECHO (Extension for Community Healthcare Outcomes), an ongoing telementoring program for healthcare professionals focusing on osteoporosis and metabolic bone diseases.

Disclosures:

Employed by New Mexico Clinical Research & Osteoporosis Center, which has received the following in the past one year: 1) Institutional Research Grant Support
 

Learning Objectives:

  • Identify patients at very high risk for fracture and determine which medications should be used for initial therapy
  • Explain the sequence of osteoporosis medication treatment to optimize increases in bone density and fracture outcomes
  • Select medications based on individual patient backgrounds and medical history.
A Paradigm Shift for the Management of Thyroid Eye Disease (TED)
Not Currently Available
Live Product Theater with Q&A
Gary J. Lelli, Jr., MD
New York-Presbyterian Hospital Weill Cornell Department of Ophthalmology, New York, New York, USA
Gary J. Lelli is Vice Chair of Ophthalmology, Director of Ophthalmic Plastic, Reconstructive, and Orbital Surgery, and Associate Professor of Ophthalmology at Weill Cornell Medical Center/New York-Presbyterian Hospital in New York, NY. Dr. Lelli completed his American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) at the combined New York City ASOPRS program, where he now serves as the fellowship director. Dr. Lelli is a member of multiple professional societies and has written numerous papers and textbook chapters. In addition to presenting at national and international meetings, Dr. Lelli actively participates in global mission work, and to this end, has taught and performed surgeries in East Africa. Dr. Lelli’s clinical interests include eyelid, orbital, and lacrimal system disorders.
sponsored by:
Horizon Therapeutics
Perioperative Management of Pituitary Tumors
Available:
SEPTEMBER 10
Anat Ben-Shlomo, MD
Cedars-Sinai Medical Center, Los Angeles, California, USA
Anat Ben-Shlomo, MD, is an Assistant Professor of Medicine at Cedars-Sinai Medical Center. She received her medical degree from Sackler Faculty of Medicine in Israel and completed her residency at Assaf HaRofeh Medical Center. Her specialties are clinical and translational-basic research in pituitary and adrenal gland disorders.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Outline pre-operative evaluation of patients with pituitary adenomas (emphasis on cortisol – should all patients be tested? what is the free T4 level that is safe?)
  • Outline post-operative management of patients with pituitary adenomas (emphasis on cortisol evaluation and replacement, diabetes insipidus and hyponatremia)
  • Describe the management of patients with pituitary adenomas in the operating room (glucocorticoid – stress dose, presence of the pathologist for Cushing’s disease (?), neuronavigation).
Pituitary Apoplexy
Not Currently Available
Garni Barkhoudarian, MD(Speaker)
Pacific Neuroscience Institute, Santa Monica, California, USA
Garni Barkhoudarian, MD, graduated from UCLA in 2000 and received his medical education at the University of Michigan Medical School in 2005. He completed his neurosurgical residency at the UCLA Medical Center. He completed a Pituitary and Neuroendoscopy Fellowship with Dr. Edward Laws at Brigham & Women’s Hospital in 2012. Dr. Barkhoudarian is a member of the American Academy of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), the International Society of Pituitary Surgeons (ISPS) and the Armenian American Medical Society (AAMS). He is a board member of the Congress of Neurological Surgeons (CNS), where he works with national colleagues to improve research, education and patient care in neurosurgery. He is an advisory board member of the Self-Assessment in Neurological Surgery (SANS) committee, writing questions to help advance the knowledge of neurosurgeons in training and in practice. Additionally, he is vice-chair of the education committee for the CNS, preparing educational content to advance neurosurgical care worldwide.

Disclosures:

Consultant: Vascular Technologies Inc.
Monica Gadelha, MD, PhD(Moderator)
Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
Monica Gadelha, MD, PhD, a member of the Brazilian National Academy of Medicine, is Professor of Endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro (UFRJ) and directs the Neuroendocrine Research Center at Hospital Universitário Clementino Fraga Filho of the UFRJ. Dra Gadelha also heads the Neuroendocrine Section and the Molecular Genetics Laboratory of the Instituto Estadual do Cérebro Paulo Niemeyer. She is a board member of the Department of Neuroendocrinology at the Brazilian Society of Endocrinology and Metabolism, as well as a researcher at Brazil’s Conselho Nacional de Desenvolvimento Cientifico e Tecnológico. She graduated at the UFRJ and performed the research and experimental part of her PhD at the University of Illinois at Chicago, IL, USA, receiving her PhD from the UFRJ. Major research interests include the molecular pathogenesis, diagnosis, and treatment of pituitary tumours. Dra Gadelha has published more than 120 peer-reviewed journal articles and book chapters and has served on the editorial boards and as a referee of several international journals.

Disclosures:

Advisory Board: Crinectics; Novartis
Research Investigator: Crinectics; Novartis
Speaker: Ipsen; Novartis
 

Learning Objectives:

  • Describe physiopathology of pituitary apoplexy: hemorrhage x ischemia
  • Summarize current medical knowledge about precipitating factors, clinical picture and diagnosis (emphasis on MRI findings in different stages) of pituitary apoplexy
  • Discuss the indications for conservative approach (emphasis on glucocorticoid dose that should be used) and surgical management of pituitary apoplexy.
Practical Approaches to Help Patients Lose Weight: Lifestyle Changes, Medications & Beyond
Not Currently Available
Robert F. Kushner, MD(Speaker)
Northwestern University, Evanston, Illinois, USA
Robert F. Kushner, MD, is a Professor of Medicine and Medical Education at the Feinburg School of Medicine at Northwestern University and Medical Director of the Wellness Institute at Northwestern Memorial Hospital in Chicago. He received his doctorate from the University of Illinois at Chicago and completed his residency at the McGaw Medical Center at Northwestern Memorial Hospital. Dr. Kushner has authored over 200 original articles, books, and book chapters covering on medical nutrition and obesity.

Disclosures:

Advisory Board: Novo Nordisk; WW (formally Weight Watchers)
Research Support: Novo Nordisk
Marc-Andre Cornier, MD(Moderator)
University of Colorado School of Medicine, Aurora, Colorado, USA
Marc-Andre Cornier, MD, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss the role of meal replacements for weight loss
  • Describe the role of anti-obesity medications and the different options available
  • Review the bariatric procedure options including endoscopic and surgical procedures.
Primary Hyperaldosteronism: Basic to More Difficult Scenarios
Not Currently Available
Irina Bancos, MD(Speaker)
Mayo Clinic, Rochester, Minnesota, USA
Irina Bancos, MD, is an Associate Professor of Medicine and adrenal endocrinologist at the Mayo Clinic in Rochester, Minnesota. She received her MD from the Iuliu Hațieganu University of Medicine and Pharmacy in Romania and completed her residency in Internal Medicine at Danbury Hospital in Connecticut. She received the 2017 and 2020 Teacher of the Year Awards in Endocrinology from the Mayo Fellows' Association.

Disclosures:

Consultant: ClinCor; Corcept Therapeutics; HRA Pharma
Dana Z. Erickson, MD(Moderator)
Mayo Clinic, Rochester, Minnesota, USA
Dana Z. Erickson, MD, is a Professor of Medicine at the Mayo College of Medicine in Rochester, MN. Her primary clinical interests include disorders of pituitary gland and adrenal disorders. She has been involved with clinical research in both of these areas, with particular interest in diagnostic laboratory methods and imaging of Cushing disease, outcomes of therapy of various pituitary tumors including acromegaly and prolactinomas, as well as studies on growth hormone secretion in aging. She served as Pituitary-adrenal-gonad core group chair at Mayo Clinic and has been involved with training of clinical endocrine fellows over the years. Dr. Erickson received her medical degree from Comenius University, Slovakia. She has completed both her medical residency and fellowship in Endocrinology, Metabolism and Nutrition at Mayo Clinic, Rochester. She is a member of Endocrine Society, Pituitary Society, AACE and over the years active member of various committees of Women in Endocrinology. Dr. Erickson is also a member of the Clinical Endocrinology Update Steering Committee.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe clinical indications when testing for primary hyperaldosteronism is indicated and select the extent of necessary confirmatory testing
  • Identify various scenarios in adrenal vein sampling interpretation
  • Recognize newer associated comorbidities described in association with hyperaldosteronism.
Thyroid Cancer Tumor Panel
Not Currently Available
Michael W. Yeh, MD(Moderator)
UCLA, Los Angeles, California, USA
Michael W. Yeh, MD, is Founder and Director of the Endocrine Surgery Program and Assistant Professor at UCLA. After pursuing his studies at Stanford University and Harvard Medical School, Dr. Yeh trained in general surgery at UC San Francisco. He then completed the prestigious T.S. Reeve International Fellowship in endocrine surgery at the Royal North Shore Hospital in Sydney, Australia. Dr. Yeh is an expert in minimally invasive parathyroid surgery, thyroid cancer, and adrenal tumors, including pheochromocytoma and adrenocortical carcinoma. He has published more than 100 scholarly articles and book chapters on these topics.

Disclosures:

No relevant financial relationships.
Electron Kebebew, MD(Panelist)
Stanford University, Stanford, California, USA
Electron Kebebew, MD, is an internationally recognized expert in Endocrine Oncology and Surgery. He has performed more than three thousand operations on the adrenal, parathyroid and thyroid glands, and for neuroendocrine tumors of the gastrointestinal tract and pancreas. Dr. Kebebew has published over 400 articles, chapters and textbooks, and serves on the editorial board and as a reviewer for 54 biomedical journals. He has received awards from the American Cancer Society, American Association for Cancer Research, American Thyroid Association, American Association of Endocrine Surgeons, and International Association of Endocrine Surgeons.

Disclosures:

No relevant financial relationships.
Angela M. Leung, MD(Panelist)
UCLA David Geffen School of Medicine, Los Angeles, California, USA
Angela M. Leung, MD, is an Associate Professor of Medicine at the UCLA David Geffen School of Medicine and an endocrinologist at both UCLA and the VA Greater Los Angeles Healthcare System. After pursuing her undergraduate studies at Occidental College, Dr. Leung completed her internal medicine residency and endocrinology fellowship training at Boston University School of Medicine. She also studied at the Boston University School of Public Health and obtained a master's degree in epidemiology. Dr. Leung has clinical and research interests in thyroid disorders and she also sees patients regarding parathyroid and adrenal disorders. She has published widely and lectures frequently on thyroid disease, including hyperthyroidism, hypothyroidism, thyroid nodules, thyroid cancer, and thyroid disease during pregnancy.

Disclosures:

Editorial Board and Editor: American Thyroid Association
 

Learning Objectives:

  • Describe appropriate initial treatment and post-operative staging of differentiated thyroid cancer
  • Summarize strategies for post-operative tumor surveillance
  • Select appropriate treatment for thyroid cancer patients with recurrent/persistent tumor.
Thyroid Nodules and Cancer in Pregnant Women
Available:
SEPTEMBER 10
Angela M. Leung, MD
UCLA David Geffen School of Medicine, Los Angeles, California, USA
Angela M. Leung, MD, is an Associate Professor of Medicine at the UCLA David Geffen School of Medicine and an endocrinologist at both UCLA and the VA Greater Los Angeles Healthcare System. After pursuing her undergraduate studies at Occidental College, Dr. Leung completed her internal medicine residency and endocrinology fellowship training at Boston University School of Medicine. She also studied at the Boston University School of Public Health and obtained a master's degree in epidemiology. Dr. Leung has clinical and research interests in thyroid disorders and she also sees patients regarding parathyroid and adrenal disorders. She has published widely and lectures frequently on thyroid disease, including hyperthyroidism, hypothyroidism, thyroid nodules, thyroid cancer, and thyroid disease during pregnancy.

Disclosures:

Editorial Board and Editor: American Thyroid Association
 

Learning Objectives:

  • Evaluate considerations regarding the timing of FNA biopsy when thyroid nodules are diagnosed during gestation
  • Define appropriate TSH targets and tumor surveillance strategies in pregnant patients with a history of thyroid cancer
  • Explain the effect of pregnancy on thyroid tumor progression.
Too Much, Too Little or Just Right: Difficult Calcium Cases
Not Currently Available
Dolores M. Shoback, MD(Speaker)
University of California, San Francisco School of Medicine, San Francisco, California, USA
Dolores M. Shoback, MD, is Professor of Medicine and Associate Program Director of the Fellowship Program in Diabetes, Endocrinology and Metabolism at the University of California, San Francisco School of Medicine. She attended the University of Pennsylvania and obtained her MD from Johns Hopkins University School of Medicine. She completed Internal Medicine residency at Johns Hopkins Hospital and her fellowship in Endocrinology and Hypertension at the Brigham and Women’s Hospital/Harvard Medical School, where she developed career-long interests in endocrine hypertension, metabolic bone disease and parathyroid disorders. Dr. Shoback is active in basic and clinical research involving calcium-sensing receptors and parathyroid disorders.

Disclosures:

Investigator: NPS (Shire, Takeda)- sponsored clinical trial REPLACE on use of PTH (1-84) in adults with hypoparathyroidism
Consultant: Ascendis Pharmaceuticals; Bridge Bio; Shire
Micol Rothman, MD(Moderator)
University of Colorado Denver, Denver, Colorado, USA
Micol Rothman, MD, is an Associate Professor of Medicine-Endocrinology with secondary appointments in Radiology and Psychiatry at the University of Colorado School of Medicine. She serves as the Clinical Director of the Metabolic Bone Program and co-founder of the UC Health Integrated Transgender Program. Her research interests include the interactions of sex steroids and the bone. She received a BA with honors in classics at Brown University in Providence, R.I. in 1993. She received her MD at the Columbia University College of Physicians and Surgeons in New York in 1999. She went on to do her internship and residency in Internal Medicine at the Johns Hopkins Hospital in Baltimore, Md., and completed this training in 2002. She then spent a year working as an internist and teaching medical students at Hubert Kairuki Memorial University in Dar Es Salaam, Tanzania. Dr. Rothman completed her fellowship in Endocrinology at the University of Colorado Health Sciences Center and began working in the Endocrinology Clinic at the Anschutz Outpatient Pavilion of University Hospital in 2006. She is board certified in both Internal Medicine and Endocrinology.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Recognize unusual causes of hypo and hypercalcemia
  • Determine best treatment strategies based on individual profiles.
Transitions in Diabetes Care: Pediatrics to Adulthood
Available:
SEPTEMBER 10
Lori Laffel, MD, MPH
Joslin Diabetes Center, Boston, Massachusetts, USA
Lori Laffel, MD, MPH, is a Professor of Pediatric at Harvard Medical School and Chief of the Pediatric, Adolescence, and Young Adult Section at Joslin Diabetes Center. She received her doctorate from the University of Miami School of Medicine and completed her residency at Children’s Hospital in Boston. Her clinical interests are maintaining and improving the health of youth with diabetes through educational and interventional approaches.

Disclosures:

Consultant: Boehringer Ingelheim; ConvaTec; Dexcom; Insulet; Insulogic; Janssen; Laxmi; LifeScan; Medtronic; Novo Nordisk; Roche; Sanofi
Grant Support: ADA; Boehringer Ingelheim; Dexcom; Eli Lilly; Helmsley Charitable Trust; Insulet; JDRF; NIH; Novo Nordisk; Sanofi
 

Learning Objectives:

  • Outline the patient-specific factors which impact diabetes control in the young adult population
  • Identify a strategic approach along with practical tools to utilize in receiving young adult patients into adult endocrinology practices
  • Discuss the benefits and challenges of diabetes technology in this patient population.
Update in Diabetic Neuropathy: Approach to Evaluation and Treatment
Available:
SEPTEMBER 10
Rodica Pop-Busui, MD, PhD
University of Michigan, Ann Arbor, Michigan, USA
Rodica Pop-Busui, MD, PhD, is a prominent diabetologist at the University of Michigan in Ann Arbor, and a nationally and internationally recognized leader in the field of diabetes as a result of her extensive clinical, research, teaching, and service activities. Dr. Pop-Busui is the site Principal Investigator and member of the Steering Committee of the newly funded NIDDK trial "PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in Type 1 Diabetes" and site Principal Investigator in the NIDDK-funded trial "Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE)." Dr. Pop-Busui has received awards from the Fulbright Foundation, the American Diabetes Association, and the University of Michigan.

Disclosures:

Research: AstraZeneca- Investigator Initiated Trial to UM
Consultant: Averitas; Bayer; Boehringer Ingelheim
Member of the Steering Committee of SOUL CVOT Trial: Novo Nordisk
 

Learning Objectives:

  • Summarize the spectrum of diabetes-associated neuropathies using a case-based approach
  • Propose a guided approach to the use of screening and diagnostic modalities
  • Describe the latest evidence-based treatment recommendations for symptoms related to diabetic neuropathy using a case-based approach.
Update on Acromegaly: Treatment Based on the New Guidelines
Available:
SEPTEMBER 10
Shlomo Melmed, MB ChB
Cedars-Sinai Medical Center, Los Angeles, California, USA
Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).

Disclosures:

Scientific Consultant: Chiasma; Crinetics; Ionis
Research Grant Support: Ipsen; Pfizer
 

Learning Objectives:

  • Translate relevant data published from the new guidelines
  • Discuss potential benefits and limitations of biomarkers in drug choice
  • Describe the new drugs in the horizon (with special emphasis on the recently FDA approved oral octreotide – which patient will benefit from this drug?).
Update on Klinefelter Syndrome: Diagnosis and Management
Available:
SEPTEMBER 10
Alvin M. Matsumoto, MD
University of Washington, Seattle, Washington, USA
Alvin M. Matsumoto, MD, directs, serves as an attending and sees patients in the GRECC Osteoporosis & Andrology Clinic, a multi-disciplinary subspecialty referral clinic for the evaluation and treatment of patients with osteoporosis and other metabolic bone disease and male hypogonadism. He also serves as an attending physician, sees patients, and teaches residents and medical students on the Geriatrics House Staff Service of Community Living Center/Transitional Care Unit at the VA Puget Sound Health Care System. Dr. Matsumoto directs the VA Special Fellowship Program in Advanced Geriatrics, a fellowship for research training in gerontology, geriatric medicine and geriatric psychiatry. Dr. Matsumoto’s research program examines the physiological and clinical effects and mechanisms of action of androgens and their active metabolites in young and aging men. Specifically, his multi-disciplinary and collaborative research program investigates androgen effects on body composition (fat mass, lean mass and bone mineral density), muscle mass and strength, metabolic function, prostate gland and cardiovascular disease, pituitary gonadotropin secretion, spermatogenesis, sexual function, cognitive function, mood and quality of life.

Disclosures:

Research Support: AbbVie
Royalty: UpToDate (Klinefelter Syndrome)
Co-Chair: Partnership for the Accurate Testing of Hormones (PATH)
 

Learning Objectives:

  • Recognize the variable phenotypes of Klinefelter syndrome during male infancy, puberty and adulthood
  • Identify the diagnostic evaluation of a male with Klinefelter syndrome based on the clinical presentation
  • Discuss the management of hypogonadism and infertility in male with Klinefelter syndrome.
An Update on Thyroid Surgery
Available:
SEPTEMBER 10
Michael W. Yeh, MD
UCLA, Los Angeles, California, USA
Michael W. Yeh, MD, is Founder and Director of the Endocrine Surgery Program and Assistant Professor at UCLA. After pursuing his studies at Stanford University and Harvard Medical School, Dr. Yeh trained in general surgery at UC San Francisco. He then completed the prestigious T.S. Reeve International Fellowship in endocrine surgery at the Royal North Shore Hospital in Sydney, Australia. Dr. Yeh is an expert in minimally invasive parathyroid surgery, thyroid cancer, and adrenal tumors, including pheochromocytoma and adrenocortical carcinoma. He has published more than 100 scholarly articles and book chapters on these topics.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe the harms and benefits related to thyroid surgery decision making strategies
  • Identify which patients with thyroid cancer are appropriate candidates for lobectomy vs. total thyroidectomy
  • Recognize strategies recommended by current guidelines.
Welcome and Introduction
Not Currently Available
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Marc-Andre Cornier, MD, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
What Endocrinologists Should Know About Female Hormonal Contraceptives
Available:
SEPTEMBER 10
Subbulaxmi Trikudanathan, MD, MMSc
University of Washington, Seattle, Washington, USA
Subbulaxmi Trikudanathan, MD, MMSc, is a Clinical Associate Professor of Medicine at the University of Washington and is the Medical Director of the UW Diabetes Institute. She obtained her medical degree from Madras Medical College in India and her MMSc from Harvard. She completed multiple residencies and fellowships in both the USA and the UK, including a final endocrinology fellowship at Brigham and Women’s Hospital in Boston, MA.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify the advantages and disadvantages of various hormonal contraceptive formulations in women of reproductive age who have common endocrinopathies including diabetes mellitus, dyslipidemia, hypothyroidism or polycystic ovary syndrome
  • Discuss how to initiate hormone contraceptives in women of reproductive age who have hirsutism and a history of risk factors for cardiovascular and thromboembolic disease
  • Explain how to initiate and manage hormonal contraceptive therapy in perimenopausal women with severe hot flashes, low bone mineral density or personal preference for such therapy.
When It's Not Your Thyroid
Not Currently Available
James V. Hennessey, MD(Speaker)
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
James V. Hennessey, MD, is an Associate Professor of Medicine at Harvard Medical School and Director of Clinical Endocrinology at Beth Israel Deaconess Medical Center. He received his degree from the University of Graz in Austria and completed his residency at the Hospital of Central Connecticut. His clinical interests include thyroid, pituitary, and adrenal disorders.

Disclosures:

No relevant financial relationships.
Tim Korevaar, MD, PhD(Moderator)
Erasmus University Medical Center, Rotterdam, Netherlands
Tim Korevaar, MD, PhD, obtained his medical degree at the Erasmus University Medical Center, Rotterdam, the Netherlands in 2013 and an MSc in clinical epidemiology at the Netherlands Institute of Health Sciences in 2015. He obtained his PhD for studies on determinants, interpretation and consequences of thyroid hormone availability during pregnancy and early life at the Erasmus University Medical Center (Cum Laude) in 2017 for which he was awarded with the Dutch Endocrine Society Thesis Award. After his PhD, he did a postdoctoral research internship at the Harvard School of Public Health (Boston, USA) studying thyroid function and fertility, and thyroid disruptors. Tim has been the recipient of the British Thyroid Award, the Society for Endocrinology Early Career Prize Lectureship award, the European Society of Endocrinology Young Investigator award and has published over 55 peer-review scientific publications and various book chapters.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Recognize the lack of specificity of most symptoms of thyroid dysfunction
  • Explain how to best communicate evidence supporting the accuracy of TSH testing as a hypothyroidism screening tool
  • Identify nonthyroidal disorders which may cause symptoms similar to thyroid dysfunction.
The Year-In Diabetes: Review of High Impact Studies 2019–2020
Not Currently Available
Janet B. McGill, MD(Speaker)
Washington University in St. Louis, St. Louis, Missouri, USA
Janet B. McGill, MD, is a Professor Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University. She received her doctorate from Michigan State University and completed her internship and residency at William Beaumont Hospital. She has been an active clinical researcher in diabetes for over 25 years and continues to test new therapies for diabetes and novel approaches to type 1 and type 2 diabetes. Currently, Dr. McGill is the principal investigator or sub-investigator on more than 10 clinical trials investigating new treatments for diabetes and its complications and serves on planning committees and data safety monitoring boards for a number of ongoing national and international clinical trials. She is a member of the board of directors for the American Association of Clinical Endocrinologists and the AACE Diabetes Scientific Committee.

Disclosures:

Consulting/Advising: Bayer; Boehringer Ingelheim; Dexcom; Lilly; Metavant; Valeritas
Grants to Washington University: Dexcom; Medtronic; NIH/Beta Bionics; Novo Nordisk
Speaking: Janssen
Cecilia Low Wang, MD(Moderator)
University Colorado Anschutz Med Campus / School of Medicine, Aurora, Colorado, USA
Cecilia Low Wang, MD, is an Endocrinologist and Professor of Medicine at the University of Colorado Anschutz Medical Campus School of Medicine, in the Division of Endocrinology, Metabolism and Diabetes, as well as Lead Clinician-Scientist at CPC Clinical Research, an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. She is the Director of the Glucose Management Team at the University of Colorado Hospital, and Director for Housestaff and Medical Student Education for the Division of Endocrinology. Dr. Low Wang attended Pomona College and earned her medical degree from the University of Rochester School of Medicine. She completed her internship and residency at the University of Utah Health Sciences Center where she also served as Chief Medical Resident. After housestaff training, she did a clinical and research fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado School of Medicine investigating insulin action in the vascular wall with a focus on vascular smooth muscle cells, and mechanisms of atherosclerosis in diabetes.

Disclosures:

Advisory Board: BioMarin Pharmaceutical Inc.; CSL Behring GMBH
Research Investigator: Novo Nordisk; uniQure
Other: Employee at CPC Clinical Research
 

Learning Objectives:

  • Summarize and provide a critical appraisal of high impact studies in the field of diabetes published in 2019-2020
  • Describe the practical clinical application of the published findings.